Policy & Regulation
Twist Bioscience, the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
18 October 2021 - - US-based synthetic biology and genomics company Twist Bioscience Corp. (NASDAQ: TWST) has inked an agreement with the Broad Institute for the distribution of a customized next-generation sequencing target enrichment exome panel designed for the identification and research of a wide range of cancer, rare and inherited disease genes from patient samples, the company said.

Twist will market this expert-developed exome panel as the Twist Alliance Clinical Research Exome.

The Twist Alliance Clinical Research Exome helps support the Broad Institute Genomics Platform and was designed using validated data from clinical patient samples.

The panel leverages Twist's flexible NGS platform to easily and quickly customize content, resulting in a comprehensive survey of the exome with supplemental enrichment of clinically relevant areas of the genome related to cancer as well as rare and inherited diseases.

By leveraging the best-in-class uniformity of Twist NGS probes, the assay enables a per sample cost and throughput efficiency that Broad has already leveraged to process more than 250,000 samples to date, keeping it on the leading edge of exome sequencing.

The Twist Alliance Clinical Research Exome will be available for customers in mid-October.

The full design of this panel includes the Twist Core exome, the mitochondrial genome, and additional validated coding and non-exonic regions of interest such as the ACMG73 genes, supplemental coverage of regions from OMIM and COSMIC, and specific Broad-defined targets.

In partnership with research institutions from around the world, Twist has curated a collection of target enrichment panels for applications ranging from carrier screening to cancer diagnostics and whole exome sequencing.

Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology.

The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip.


Related Headlines